Rescue of enzyme deficiency in embryonic diaphragm in a mouse model of metabolic myopathy: Pompe disease
Open Access
- 15 June 2004
- journal article
- Published by The Company of Biologists in Development
- Vol. 131 (12) , 3007-3019
- https://doi.org/10.1242/dev.01169
Abstract
Several human genetic diseases that affect striated muscle have been modeled by creating knockout mouse strains. However, many of these are perinatal lethal mutations that result in death from respiratory distress within hours after birth. As the diaphragm muscle does not contract until birth, the sudden increase in diaphragm activity creates permanent injury to the muscle causing it to fail to meet respiratory demands. Therefore, the impact of these mutations remains hidden throughout embryonic development and early death prevents investigators from performing detailed studies of other striated muscle groups past the neonatal stage. Glycogen storage disease type II (GSDII), caused by a deficiency in acid α-glucosidase (GAA), leads to lysosomal accumulation of glycogen in all cell types and abnormal myofibrillogenesis in striated muscle. Contractile function of the diaphragm muscle is severely affected in both infantile-onset and late-onset individuals, with death often resulting from respiratory failure. The knockout mouse model of GSDII survives well into adulthood despite the gradual weakening of all striated muscle groups. Using this model, we investigated the delivery of recombinant adeno-associated virus (rAAV) vectors encoding the human GAA cDNA to the developing embryo. Results indicate specific high-level transduction of diaphragm tissue, leading to activity levels up to 10-fold higher than normal and restoration of normal contractile function. Up to an estimated 50 vector copies per diploid genome were quantified in treated diaphragms. Histological glycogen staining of treated diaphragms revealed prevention of lysosomal glycogen accumulation in almost all fibers when compared with untreated controls. This method could be employed with disease models where specific rescue of the diaphragm would allow for increased survival and thus further investigation into the impact of the gene deletion on other striated muscle groups.Keywords
This publication has 45 references indexed in Scilit:
- Efficacy of Gene Therapy for a Prototypical Lysosomal Storage Disease (GSD-II) Is Critically Dependent on Vector Dose, Transgene Promoter, and the Tissues Targeted for Vector TransductionMolecular Therapy, 2002
- Prevention of systemic clinical disease in MPS VII mice following AAV-mediated neonatal gene transferGene Therapy, 2001
- Safety and Efficacy of Recombinant Human α-Galactosidase A Replacement Therapy in Fabry's DiseaseNew England Journal of Medicine, 2001
- Long-Term Efficacy after [E1-, polymerase-] Adenovirus-Mediated Transfer of Human Acid-α-Glucosidase Gene into Glycogen Storage Disease Type II Knockout MiceHuman Gene Therapy, 2001
- Towards a molecular therapy for glycogen storage disease type II (Pompe disease)Molecular Medicine Today, 2000
- Systemic correction of the muscle disorder glycogen storage disease type II after hepatic targeting of a modified adenovirus vector encoding human acid-α-glucosidaseProceedings of the National Academy of Sciences, 1999
- Molecular Pathophysiology of Cystic Fibrosis Based on the Rescued Knockout Mouse ModelMolecular Genetics and Metabolism, 1998
- Foetal gene delivery in mice by intra-amniotic administration of retroviral producer cells and adenovirusGene Therapy, 1997
- Mini-dystrophin gene transfer in mdx4cv diaphragm muscle fibers increases sarcolemmal stabilityGene Therapy, 1997
- Contractile properties of skeletal muscles from young, adult and aged mice.The Journal of Physiology, 1988